Eckert & Ziegler to Supply Clinical-Grade Y90-PentixaTher Doses for Pentixapharm Trials

Eckert & Ziegler to Supply Clinical-Grade Y90-PentixaTher Doses for Pentixapharm Trials

(IN BRIEF) Eckert & Ziegler Radiopharma GmbH has entered into a clinical manufacturing agreement with Pentixapharm AG to supply GMP-grade Y90-PentixaTher doses for use in ongoing trials. The radiolabeled therapy targets cancers overexpressing the CXCR4 receptor and supports a theranostic model with Ga68-PentixaFor. EZR will oversee production and distribution of patient-specific doses during clinical development, while Pentixapharm retains future commercial strategy control.

(PRESS RELEASE) BERLIN, 25-Apr-2025 — /EuropaWire/ — Eckert & Ziegler Radiopharma GmbH (EZR), a wholly owned subsidiary of Eckert & Ziegler SE, has signed a manufacturing agreement with Pentixapharm AG to support the clinical advancement of Y90-PentixaTher, a promising CXCR4-targeting radiopharmaceutical therapy. Under the terms of the agreement, EZR will manufacture and distribute patient-specific doses of the compound under GMP conditions for clinical trial use.

Y90-PentixaTher is a radiolabeled peptide therapeutic designed to selectively deliver radiation to cancer cells that overexpress the CXCR4 receptor—frequently seen in malignancies such as acute myeloid leukemia, lymphoma, myeloma, and a range of solid tumors. The therapy is part of a theranostic approach, used in combination with Ga68-PentixaFor to visualize and monitor disease progression and response to treatment.

EZR will manage the manufacturing process and coordinate direct shipments of the therapeutic to clinical trial sites. The agreement is specific to the clinical development phase, and Pentixapharm retains complete strategic freedom regarding future commercial supply and manufacturing decisions.

“We are pleased to contribute to Pentixapharm’s clinical development by ensuring consistent, high-quality access to Y90-PentixaTher,” said Dr. Harald Hasselmann, CEO of Eckert & Ziegler SE. “Our goal is to support the next generation of targeted radiopharmaceuticals by leveraging our expertise in GMP manufacturing and radioisotope delivery.”

“This collaboration represents a vital milestone for us,” added Dr. Dirk Pleimes, CEO of Pentixapharm AG. “With EZR’s production capabilities, we are now well-positioned to advance our radiotherapeutic pipeline and maintain a reliable clinical supply chain as we move toward late-stage development.”